BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Alhaj-suliman SO, Wafa EI, Salem AK. Engineering nanosystems to overcome barriers to cancer diagnosis and treatment. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2022.114482] [Reference Citation Analysis]
2 Gerbaudo VH, Latif MA. A Step Forward in PET-Based Quantitation of G3 Neuroendocrine Tumor Aggressiveness - The FDZ Score…. Acad Radiol 2022:S1076-6332(22)00140-4. [PMID: 35365399 DOI: 10.1016/j.acra.2022.03.001] [Reference Citation Analysis]
3 Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers (Basel) 2022;14:1172. [PMID: 35267479 DOI: 10.3390/cancers14051172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee H, Nakamoto R, Moore SE, Pantel AR, Eads JR, Aparici CM, Pryma DA. Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Academic Radiology 2021. [DOI: 10.1016/j.acra.2021.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kasprzak A. Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines 2021;9:1743. [PMID: 34829972 DOI: 10.3390/biomedicines9111743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Raabe M, Heck AJ, Führer S, Schauenburg D, Pieszka M, Wang T, Zegota MM, Nuhn L, Ng DYW, Kuan SL, Weil T. Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates. Macromol Biosci 2021;:e2100299. [PMID: 34791790 DOI: 10.1002/mabi.202100299] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Al-Mansoori L, Elsinga P, Goda SK. Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy. Biomed Pharmacother 2021;144:112260. [PMID: 34607105 DOI: 10.1016/j.biopha.2021.112260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Mahadik N, Bhattacharya D, Padmanabhan A, Sakhare K, Narayan KP, Banerjee R. Targeting steroid hormone receptors for anti-cancer therapy-A review on small molecules and nanotherapeutic approaches. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1755. [PMID: 34541822 DOI: 10.1002/wnan.1755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
10 Mullangi S, Lekkala MR, Raghu Subramanian C, Nemer O, Singh J, Kichloo A, Moftakhar B. Incidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan. J Investig Med High Impact Case Rep 2021;9:23247096211035232. [PMID: 34311624 DOI: 10.1177/23247096211035232] [Reference Citation Analysis]
11 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
12 Cohen L, Livney YD, Assaraf YG. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat 2021;56:100762. [PMID: 33857756 DOI: 10.1016/j.drup.2021.100762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Klusa D, Lohaus F, Furesi G, Rauner M, Benešová M, Krause M, Kurth I, Peitzsch C. Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. Front Oncol 2020;10:627379. [PMID: 33747899 DOI: 10.3389/fonc.2020.627379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Artale S, Barzaghi S, Grillo N, Maggi C, Lepori S, Butti C, Bovio A, Barbarini L, Colombo A, Zanlorenzi L, Castiglioni E, Trojani A. Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors. Nutr Cancer 2020;:1-10. [PMID: 33148022 DOI: 10.1080/01635581.2020.1838572] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Klomp MJ, Dalm SU, de Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord 2021;22:495-510. [PMID: 33085037 DOI: 10.1007/s11154-020-09607-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
16 Kokov K, Demchenko A, Egorova B, Larkin A, Lyundup A, Makoveeva K, Moiseeva A, Panchenko V, Proshin M, Reshetov I, Chuvilin D. Production and Investigation of Radiopharmaceutical Nanoconstruction [212Pb]DOTATATE for Therapy of Malignant Neoplasms. J Synch Investig 2020;14:S99-S104. [DOI: 10.1134/s102745102007023x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Costanzi E, Simioni C, Conti I, Laface I, Varano G, Brenna C, Neri LM. Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives. J Cell Physiol 2021;236:2505-18. [PMID: 32989768 DOI: 10.1002/jcp.30062] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
19 Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16:590-607. [PMID: 32839579 DOI: 10.1038/s41574-020-0391-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
20 Ampofo E, Nalbach L, Menger MD, Laschke MW. Regulatory Mechanisms of Somatostatin Expression. Int J Mol Sci 2020;21:E4170. [PMID: 32545257 DOI: 10.3390/ijms21114170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
21 Poudel K, Thapa RK, Gautam M, Ou W, Soe ZC, Gupta B, Ruttala HB, Thuy HN, Dai PC, Jeong J, Ku SK, Choi H, Yong CS, Kim JO. Multifaceted NIR-responsive polymer-peptide-enveloped drug-loaded copper sulfide nanoplatform for chemo-phototherapy against highly tumorigenic prostate cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2019;21:102042. [DOI: 10.1016/j.nano.2019.102042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
22 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
23 Storvall S, Leijon H, Ryhänen E, Louhimo J, Haglund C, Schalin-Jäntti C, Arola J. Somatostatin receptor expression in parathyroid neoplasms. Endocr Connect 2019;8:1213-23. [PMID: 31336364 DOI: 10.1530/EC-19-0260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
24 Tao L, Chen Y, Huang Q, Yong J, Yan S, Huang Y. Constant expression of somatostatin receptor 2a in minute pulmonary meningothelial-like nodules. J Clin Pathol 2019;72:525-8. [DOI: 10.1136/jclinpath-2019-205913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Solomonov AV, Marfin YS, Rumyantsev EV, Ragozin E, Zahavi TS, Gellerman G, Tesler AB, Muench F, Kumagai A, Miyawaki A. Self-assembled micellar clusters based on Triton-X-family surfactants for enhanced solubilization, encapsulation, proteins permeability control, and anticancer drug delivery. Materials Science and Engineering: C 2019;99:794-804. [DOI: 10.1016/j.msec.2019.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
26 Tao L, Huang Y, Chen Y, Yu G, Yin W. SSTR2a Is a Useful Diagnostic Marker for Follicular Dendritic Cells and Their Related Tumors. American Journal of Surgical Pathology 2019;43:374-81. [DOI: 10.1097/pas.0000000000001205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
27 White BH, Whalen K, Kriksciukaite K, Alargova R, Au Yeung T, Bazinet P, Brockman A, DuPont M, Oller H, Lemelin CA, Lim Soo P, Moreau B, Perino S, Quinn JM, Sharma G, Shinde R, Sweryda-Krawiec B, Wooster R, Bilodeau MT. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo. J Med Chem 2019;62:2708-19. [PMID: 30735385 DOI: 10.1021/acs.jmedchem.8b02036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
28 Kucharava K, Sekulic-Jablanovic M, Horvath L, Bodmer D, Petkovic V. Pasireotide protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K-Akt pathway. Cell Death Dis 2019;10:110. [PMID: 30728348 DOI: 10.1038/s41419-019-1386-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
29 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 31.0] [Reference Citation Analysis]
30 Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A. Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. Onco Targets Ther 2019;12:319-39. [PMID: 30643430 DOI: 10.2147/OTT.S182685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Lehman JM, Hoeksema MD, Staub J, Qian J, Harris B, Callison JC, Miao J, Shi C, Eisenberg R, Chen H, Chen SC, Massion PP. Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. Int J Cancer 2019;144:1104-14. [PMID: 30152518 DOI: 10.1002/ijc.31771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
32 Sliwinska-Mosson M, Marek G, Grzebieniak Z, Milnerowicz H. Relationship between somatostatin and interleukin-6: A cross-sectional study in patients with acute pancreatitis. Pancreatology 2018;18:885-91. [PMID: 30279074 DOI: 10.1016/j.pan.2018.09.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Paramonov VM, Desai D, Kettiger H, Mamaeva V, Rosenholm JM, Sahlgren C, Rivero-Müller A. Targeting Somatostatin Receptors By Functionalized Mesoporous Silica Nanoparticles - Are We Striking Home? Nanotheranostics 2018;2:320-46. [PMID: 30148051 DOI: 10.7150/ntno.23826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
34 Subramaniam RM. Section Editor's Notebook: 68 Ga- and 177 Lu-DOTATATE Theragnostics—Personalized Care and Improving Patient Outcomes. American Journal of Roentgenology 2018;211:244-5. [DOI: 10.2214/ajr.18.20279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Alzugaray ME, Ronderos JR. Allatoregulatory-like systems and changes in cytosolic Ca2+ modulate feeding behavior in Hydra. General and Comparative Endocrinology 2018;258:70-8. [DOI: 10.1016/j.ygcen.2017.07.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Dickinson PS, Armstrong MK, Dickinson ES, Fernandez R, Miller A, Pong S, Powers BW, Pupo-Wiss A, Stanhope ME, Walsh PJ, Wiwatpanit T, Christie AE. Three members of a peptide family are differentially distributed and elicit differential state-dependent responses in a pattern generator-effector system. J Neurophysiol 2018;119:1767-81. [PMID: 29384453 DOI: 10.1152/jn.00850.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
37 Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, Yang P, Chen S, Ye M, Duan S. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 2017;630:1-7. [PMID: 28782576 DOI: 10.1016/j.gene.2017.07.082] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
38 Marciniak A, Brasuń J. Somatostatin analogues labeled with copper radioisotopes: current status. J Radioanal Nucl Chem 2017;313:279-89. [PMID: 28804185 DOI: 10.1007/s10967-017-5323-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
39 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
41 Golabi-dezfoli A, Yousefnia H, Hosntalab M, Zolghadri S. Optimized production, quality control and biodistribution assessment of 166Ho–DOTATOC: a novel radiolabelled somatostatin analog. J Radioanal Nucl Chem 2017;312:329-35. [DOI: 10.1007/s10967-017-5225-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 2017;20:100-8. [DOI: 10.1007/s11102-017-0791-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
43 de la Cueva L, Lloro P, Sangrós MJ, López Vélez L, Navarro P, Sarria L, Álvarez S, Abós D. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy. Clin Transl Oncol 2017;19:915-20. [PMID: 28144828 DOI: 10.1007/s12094-017-1616-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Ellert-Miklaszewska A, Poleszak K, Kaminska B. Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment. Future Med Chem 2017;9:199-221. [PMID: 28111982 DOI: 10.4155/fmc-2016-0189] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
45 Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Pacak K, Zhuang Z, Chittiboina P. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Sci Rep 2017;7:40822. [PMID: 28094316 DOI: 10.1038/srep40822] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
46 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Kuan SL, Wang T, Weil T. Site-Selective Disulfide Modification of Proteins: Expanding Diversity beyond the Proteome. Chemistry 2016;22:17112-29. [PMID: 27778400 DOI: 10.1002/chem.201602298] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
48 Shekhter zahavi T, Oron-herman M, Kostenich G, Rub E, Salitra Y, Buzhansky L, Orenstein A, Gazit E, Adler-abramovich L. Molecular Engineering of Somatostatin Analogue with Minimal Dipeptide Motif Induces the Formation of Functional Nanoparticles. ChemNanoMat 2017;3:27-32. [DOI: 10.1002/cnma.201600220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Villalobos-sambucaro MJ, Diambra LA, Noriega FG, Ronderos JR. Allatostatin-C antagonizes the synergistic myostimulatory effect of allatotropin and serotonin in Rhodnius prolixus ( Stal ). General and Comparative Endocrinology 2016;233:1-7. [DOI: 10.1016/j.ygcen.2016.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
50 Wang M, Shan F, Zou Y, Sun X, Zhang Z, Fu Y, Gong T. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. Journal of Controlled Release 2016;230:45-56. [DOI: 10.1016/j.jconrel.2016.03.036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
51 Maaß C, Rivas JR, Attarwala AA, Hardiansyah D, Niedermoser S, Litau S, Wängler C, Wängler B, Glatting G. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice. Nucl Med Biol 2016;43:243-6. [PMID: 27067044 DOI: 10.1016/j.nucmedbio.2016.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Śliwińska-mossoń M, Jeleń M, Milnerowicz H. Somatostatin expression in the pancreatic cells of smoking and non-smoking chronic pancreatitis patients with or without diabetes. Pancreatology 2016;16:225-30. [DOI: 10.1016/j.pan.2015.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
53 Kuan SL, Wang T, Raabe M, Liu W, Lamla M, Weil T. Programming Bioactive Architectures with Cyclic Peptide Amphiphiles. Chempluschem 2015;80:1347-53. [PMID: 31973290 DOI: 10.1002/cplu.201500218] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015;76:481-487. [PMID: 26126727 DOI: 10.1007/s00280-015-2814-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
55 Brogsitter C, Hofmockel T, Kotzerke J. (68)Ga DOTATATE uptake in vertebral hemangioma. Clin Nucl Med 2014;39:462-3. [PMID: 24152639 DOI: 10.1097/RLU.0000000000000282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
56 Barbieri F, Thellung S, Würth R, Gatto F, Corsaro A, Villa V, Nizzari M, Albertelli M, Ferone D, Florio T. Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. Int J Endocrinol 2014;2014:753524. [PMID: 25484899 DOI: 10.1155/2014/753524] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
57 Blum AP, Kammeyer JK, Yin J, Crystal DT, Rush AM, Gilson MK, Gianneschi NC. Peptides displayed as high density brush polymers resist proteolysis and retain bioactivity. J Am Chem Soc 2014;136:15422-37. [PMID: 25314576 DOI: 10.1021/ja5088216] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
58 Śliwińska-mossoń M, Veselý M, Milnerowicz H. The clinical significance of somatostatin in pancreatic diseases. Annales d'Endocrinologie 2014;75:232-40. [DOI: 10.1016/j.ando.2014.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
59 Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today 2014;19:458-68. [DOI: 10.1016/j.drudis.2013.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
60 Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-guibert J, Pyronnet S, Bousquet C. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends in Endocrinology & Metabolism 2014;25:115-27. [DOI: 10.1016/j.tem.2013.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
61 Würth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int 2014;2014:126586. [PMID: 24527434 DOI: 10.1155/2014/126586] [Cited by in Crossref: 43] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
62 Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2014;19:79-97. [PMID: 24400774 DOI: 10.1517/14728214.2014.875529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
63 Martín-Gago P, Aragón E, Gomez-Caminals M, Fernández-Carneado J, Ramón R, Martin-Malpartida P, Verdaguer X, López-Ruiz P, Colás B, Cortes MA, Ponsati B, Macias MJ, Riera A. Insights into structure-activity relationships of somatostatin analogs containing mesitylalanine. Molecules 2013;18:14564-84. [PMID: 24287991 DOI: 10.3390/molecules181214564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
64 Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228-52. [PMID: 23872332 DOI: 10.1016/j.yfrne.2013.07.005] [Cited by in Crossref: 170] [Cited by in F6Publishing: 182] [Article Influence: 18.9] [Reference Citation Analysis]
65 Behnammanesh H, Erfani M, Hajiramezanali M, Jokar S, Geramifar P, Sabzevari O, Amini M, Mazidi SM, Beiki D. Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells. Asia Ocean J Nucl Med Biol 2020;8:109-15. [PMID: 32714998 DOI: 10.22038/AOJNMB.2020.44432.1299] [Cited by in F6Publishing: 2] [Reference Citation Analysis]